Semax | Peptide Research Hub

At a Glance

Semax is a peptide analog discussed in neurocognitive contexts, with a body of literature that is regionally concentrated. A clinical/electrophysiological report (Russian-language) describes semax use in acute hemispheric ischemic stroke. [PMID: 11517472]

⚠️ Research Status: Semax is not an approved medication in many jurisdictions. This page is educational and intentionally does not include protocols/dosing.

Mechanism of Action (TBD)

Mechanistic framing varies (often neurotrophic/neuroprotective in preclinical models) and should be supported with primary sources for any specific claim.

Evidence Summary

Low Confidence Observational >10 Years

Clinical/electrophysiological report (Russian-language) describing semax use in acute ischemic stroke. [PMID: 11517472]

Safety & Unknowns

Evidence quality and reporting varies by source and region.
Safety and efficacy cannot be generalized from limited, hard-to-audit sources.

Regulatory Status

Region	Status
United States (FDA)	Not approved
European Union (EMA)	Not approved
WADA	Check current list (status may change)

Changelog

Date	Change
2026-01-23	Added dossier and linked primary literature